Analysts Offer Insights on Healthcare Companies: Solventum Corporation (SOLV) and Praxis Precision Medicines (PRAX)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Solventum Corporation (SOLV – Research Report) and Praxis Precision Medicines (PRAX – Research Report).
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Solventum Corporation (SOLV)
Bank of America Securities analyst Travis Steed maintained a Hold rating on Solventum Corporation today and set a price target of $85.00. The company’s shares closed last Friday at $80.30, close to its 52-week high of $85.92.
According to TipRanks.com, Steed is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Solventum Corporation with a $93.71 average price target, implying a 17.0% upside from current levels. In a report issued on January 13, Wells Fargo also maintained a Hold rating on the stock with a $86.00 price target.
See the top stocks recommended by analysts >>
Praxis Precision Medicines (PRAX)
JonesTrading analyst Justin Walsh reiterated a Buy rating on Praxis Precision Medicines today and set a price target of $441.00. The company’s shares closed last Friday at $301.45.
According to TipRanks.com, Walsh is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Praxis Precision Medicines with a $470.69 average price target, a 57.4% upside from current levels. In a report issued on January 5, Needham also maintained a Buy rating on the stock with a $460.00 price target.
